Pharmacodiagnostic evaluation of EGFR expression in oral squamous cell carcinoma.
OBJECTIVE
To determine epidermal growth factor receptor (EGFR) expression in oral squamous cell carcinomas (OSCC), and its possible relationships with clinical findings, histological findings, disease course and prognosis.


METHODS
Surgical specimens of 47 OSCCs were studied immunohistochemically for detection of EGFR using a standardized immunohistochemical detection system (EGFR PharmaDx kit). Statistical analysis was used to investigate possible relationships between EGFR expression and clinical findings, histological findings, cell proliferation (MIB1 labelling index), disease course and patient survival.


RESULTS
Epidermal growth factor receptor expression was absent or weak in 12 cases (25.5%) and moderate or intense in 35 cases (74.5%). However, EGFR expression did not show statistically significant associations with any of the clinical, histological, biological or prognostic variables considered.


CONCLUSIONS
First, despite previous suggestions that EGFR is a useful indicator of biological tumour behaviour, the present results suggest that EGFR is not a useful indicator of prognosis in OSCC. Secondly, the high prevalence of EGFR overexpression suggests that the possibility of anti-EGFR therapy in OSCC merits further investigation.
Diniz-Freitas
M
M
Oral Surgery Department, School of Dentistry, Santiago de Compostela, Spain. cidinizm@usc.es
García-Caballero
T
T
Antúnez-López
J
J
Gándara-Rey
J M
JM
García-García
A
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D002294:Carcinoma, Squamous Cell / Q000737:chemistry / Q000378:metabolism* / Q000473:pathology; D049109:Cell Proliferation; D016009:Chi-Square Distribution; D066246:ErbB Receptors / Q000032:analysis / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000737:chemistry / Q000378:metabolism* / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D011933:Reagent Kits, Diagnostic
D014408:Biomarkers, Tumor; D011933:Reagent Kits, Diagnostic; D066246:ErbB Receptors